08:00 , Dec 24, 2012 |  BC Week In Review  |  Clinical News

DPK-060: Phase II data

Top-line data from a double-blind, placebo-controlled, Swedish Phase II trial in 69 patients with acute external otitis caused by bacterial or fungal pathogens showed that thrice-daily DPK-060 2% ear drops for 7-10 days was safe...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Company News

BioCis Pharma Ltd., Lx Therapies deal

BioCis and Lx Therapies merged to form Laurantis Pharma Oy . The newco hired Riku Rautsola, former president and CEO of Virxsys Corp. (Gaithersburg, Md.), as president and CEO. Laurantis' lead candidates target inflammatory diseases,...
08:00 , Mar 7, 2011 |  BC Week In Review  |  Company News

Pergamum, Karolinska Development dermatology, musculoskeletal news

Karolinska disclosed in its 2010 earnings that in December, Pergamum acquired full ownership of Lipopeptide AB, PharmaSurgics AB and DermaGen AB. In 2009, Karolinska combined its portfolio companies DermaGen, Lipopeptide, Omnio Healer AB, BioCis Pharma...
07:00 , Sep 14, 2009 |  BC Week In Review  |  Company News

Karolinska Development dermatology, musculoskeletal news

Karolinska combined its portfolio companies DermaGen AB (Lund, Sweden), Lipopeptide AB (Stockholm, Sweden) and PharmaSurgics AB (Gothenburg, Sweden), into newco Pergamum AB . Karolinska also transferred its minority holdings in Omnio Healer AB (Umea, Sweden)...
07:00 , Jul 13, 2009 |  BC Week In Review  |  Clinical News

ProtoCure emulsion cream: Phase IIa data

In a 28-day, double-blind, Finnish Phase IIa trial in 13 patients with mild-to-moderate atopic dermatitis, ProtoCure significantly decreased skin redness and improved skin barrier function compared with placebo. ProtoCure significantly improved EASI scores vs. baseline...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Clinical News

ProtoCure instillation solution: Phase I started

BioCis began an open-label, dose-escalation, Finnish Phase I trial to evaluate intravesical ProtoCure instillation solution in 22 patients with primary or recurrent non-muscle invasive bladder cancer. BioCis Pharma Ltd. , Turku, Finland   Product: ProtoCure...
07:00 , Mar 16, 2009 |  BC Week In Review  |  Clinical News

ProtoCure: Phase IIa started

BioCis began a double-blind, vehicle-controlled Phase IIa trial to evaluate topical ProtoCure for up to 4 weeks in 18 patients. BioCis Pharma Ltd. , Turku, Finland   Product: ProtoCure   Business: Autoimmune   Molecular target:...
08:00 , Nov 10, 2008 |  BC Week In Review  |  Clinical News

ProtoCure: Phase IIa started

BioCis began a double-blind, vehicle-controlled Phase IIa trial of topical ProtoCure in 18 patients. BioCis Pharma Ltd. , Turku, Finland   Product: ProtoCure   Business: Dermatology   Molecular target: NA   Description: Emulsion cream  ...
07:00 , Mar 10, 2008 |  BC Week In Review  |  Clinical News

ProtoCure: Phase I started

BioCis began a double-blind, placebo-controlled, Finnish Phase I trial of topical ProtoCure in healthy volunteers. BioCis Pharma Ltd. , Turku, Finland   Product: ProtoCure   Business: Dermatology   Molecular target: NA   Description: Emulsion cream...